» Articles » PMID: 33727527

Biomaterial-based Strategies for Maxillofacial Tumour Therapy and Bone Defect Regeneration

Overview
Journal Int J Oral Sci
Date 2021 Mar 17
PMID 33727527
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Issues caused by maxillofacial tumours involve not only dealing with tumours but also repairing jaw bone defects. In traditional tumour therapy, the systemic toxicity of chemotherapeutic drugs, invasive surgical resection, intractable tumour recurrence, and metastasis are major threats to the patients' lives in the clinic. Fortunately, biomaterial-based intervention can improve the efficiency of tumour treatment and decrease the possibility of recurrence and metastasis, suggesting new promising antitumour therapies. In addition, maxillofacial bone tissue defects caused by tumours and their treatment can negatively affect the physiological and psychological health of patients, and investment in treatment can result in a multitude of burdens to society. Biomaterials are promising options because they have good biocompatibility and bioactive properties for stimulation of bone regeneration. More interestingly, an integrated material regimen that combines tumour therapy with bone repair is a promising treatment option. Herein, we summarized traditional and biomaterial-mediated maxillofacial tumour treatments and analysed biomaterials for bone defect repair. Furthermore, we proposed a promising and superior design of dual-functional biomaterials for simultaneous tumour therapy and bone regeneration to provide a new strategy for managing maxillofacial tumours and improve the quality of life of patients in the future.

Citing Articles

Gingival fibroblast suppress the osteogenesis process mediated by bone substitute materials via WNT/β-catenin signaling pathway and .

Liu G, Lin J, Chen X, Liu R Front Bioeng Biotechnol. 2025; 13:1521134.

PMID: 39995594 PMC: 11847790. DOI: 10.3389/fbioe.2025.1521134.


Advancements in Bone Replacement Techniques-Potential Uses After Maxillary and Mandibular Resections Due to Medication-Related Osteonecrosis of the Jaw (MRONJ).

Bovari-Biri J, Miskei J, Kover Z, Steinerbrunner-Nagy A, Kardos K, Maroti P Cells. 2025; 14(2).

PMID: 39851573 PMC: 11763601. DOI: 10.3390/cells14020145.


[Research progress of bioactive scaffolds in repair and regeneration of osteoporotic bone defects].

Wu Y, Sun K, Zeng Y, Shen B Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2025; 39(1):100-105.

PMID: 39848724 PMC: 11757963. DOI: 10.7507/1002-1892.202410018.


ZnSnO@SiO@5-FU Nanoparticles as an Additive for Maxillary Bone Defects.

Rehner Costache A, Bratu A, Birca A, Niculescu A, Holban A, Hudita A Int J Mol Sci. 2025; 26(1.

PMID: 39796051 PMC: 11720676. DOI: 10.3390/ijms26010194.


Skeletal interoception and prospective application in biomaterials for bone regeneration.

Bai L, Li J, Li G, Zhou D, Su J, Liu C Bone Res. 2025; 13(1):1.

PMID: 39743568 PMC: 11693760. DOI: 10.1038/s41413-024-00378-w.


References
1.
Ettinger K, Ganry L, Fernandes R . Oral Cavity Cancer. Oral Maxillofac Surg Clin North Am. 2018; 31(1):13-29. DOI: 10.1016/j.coms.2018.08.002. View

2.
Ettinger K, Yetzer J . Controversies in Oral and Maxillofacial Oncology. Oral Maxillofac Surg Clin North Am. 2017; 29(4):487-501. DOI: 10.1016/j.coms.2017.07.004. View

3.
Marur S, Forastiere A . Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016; 91(3):386-96. DOI: 10.1016/j.mayocp.2015.12.017. View

4.
Santosh A, Ogle O . Odontogenic Tumors. Dent Clin North Am. 2019; 64(1):121-138. DOI: 10.1016/j.cden.2019.08.008. View

5.
Peacock Z . Adjunctive Strategies for Benign Maxillofacial Pathology. Oral Maxillofac Surg Clin North Am. 2019; 31(4):569-578. DOI: 10.1016/j.coms.2019.07.002. View